MannKind Corporation · 3 hours ago
Quality Control Internship
Danbury, CT
Internship
Onsite
InternMannKind Corporation is a biopharmaceutical company dedicated to transforming chronic disease care through innovative solutions. They are seeking a Quality Control Intern to learn laboratory operations, improve compliance and efficiency, and contribute to various projects within the Quality Control department.
BiotechnologyHealth CarePharmaceutical
No H1B
Responsibilities
Learn how the Quality Control laboratory operates and propose suggestions for improvement to increase laboratory compliance and efficiency
Work with the team to build a more robust HPLC/GC column inventory and storage tracking system
Maintain and improve chemical and reference standard inventory program
Help build an instrument usage tracking system to increase laboratory efficiency
Look into ways AI can help improve laboratory compliance and efficiency
Qualification
Required
Pursuing a bachelor's degree in a science related discipline
A reliable commute or the intention to find temporary housing before starting the internship is required
At this time, we are only able to consider candidates who do not require visa sponsorship, including those with a student visa
Preferred
Preferably within 1-2 years of graduation
Strong analytical, interpersonal, organizational, and problem-solving skills
Excellent attention to detail and ability to work independently
Proficiency in Microsoft Office
Strong written and verbal communication skills
Self-motivated and demonstrated learning agility
You take the initiative to identify opportunities for improvement and act on them without needing constant direction
You are open to constructive criticism and use it to improve performance and grow professionally
Company
MannKind Corporation
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions.
Founded in 2001
501-1000 employees
Funding
Current Stage
Public CompanyTotal Funding
$475MKey Investors
Blackstone GroupDeerfield Capital Management
2025-08-06Post Ipo Debt· $75M
2021-03-02Post Ipo Debt· $200M
2018-12-01Post Ipo Equity· $40M
Leadership Team
Michael Castagna
Chief Executive Officer
Christopher Prentiss
Chief Financial Officer
Recent News
2026-01-15
2026-01-09
GlobeNewswire
2025-12-24
Company data provided by crunchbase